Literature DB >> 17434894

The expanding role of PET technology in the management of patients with colorectal cancer.

R A Herbertson1, S T Lee, N Tebbutt, A M Scott.   

Abstract

The therapeutic options and subsequent survival of colorectal cancer (CRC) patients has increased substantially over recent years. While surgical excision of the primary cancer results in cure of approximately 50% of patients, recurrence and metastatic disease still remains a significant cause of death. Although resection of liver or lung metastases can result in cure, relapse rates remain high, indicating that patient selection needs improvement. Positron emission tomography (PET) technology has a great deal to offer with respect to CRC management, particularly in the setting of patient selection for metastasectomy and in the evaluation of possible recurrent disease, however it has not yet become a routine part of the management of all CRC patients. This review article aims to discuss the current and future implications of PET technology in the optimal management of CRC patients throughout their care pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17434894     DOI: 10.1093/annonc/mdm108

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  6 in total

1.  Application of (18)F-fluorodeoxyglucose positron emission tomography to detection of proximal lesions of obstructive colorectal cancer.

Authors:  Shusuke Mori; Kazuhiro Oguchi
Journal:  Jpn J Radiol       Date:  2010-10-24       Impact factor: 2.374

2.  FDG-PET/CT-guided biopsy of bone metastases sets a new course in patient management after extensive imaging and multiple futile biopsies.

Authors:  M K Werner; P Aschoff; M Reimold; C Pfannenberg
Journal:  Br J Radiol       Date:  2011-03       Impact factor: 3.039

Review 3.  [Modern imaging of liver metastases].

Authors:  J Breitenseher; M Pones; G Wengert; A Ba-Ssalamah
Journal:  Radiologe       Date:  2015-01       Impact factor: 0.635

4.  PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences.

Authors:  Bernd Klaeser; Michel D Mueller; Ralph A Schmid; Carlos Guevara; Thomas Krause; Jakub Wiskirchen
Journal:  Eur Radiol       Date:  2009-02-24       Impact factor: 5.315

5.  STa peptide analogs for probing guanylyl cyclase C.

Authors:  Xiaobing Tian; Allison M Michal; Peng Li; Henry R Wolfe; Scott A Waldman; Eric Wickstrom
Journal:  Biopolymers       Date:  2008       Impact factor: 2.505

6.  Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities.

Authors:  F Cornelis; M Silk; H Schoder; H Takaki; J C Durack; J P Erinjeri; C T Sofocleous; R H Siegelbaum; M Maybody; S B Solomon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-09       Impact factor: 9.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.